AIMT - Aimmune Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.20
-0.01 (-0.04%)
As of 9:34AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close24.21
Open24.17
Bid22.69 x 800
Ask0.00 x 1100
Day's Range24.18 - 24.28
52 Week Range16.95 - 36.12
Volume9,186
Avg. Volume986,660
Market Cap1.517B
Beta (3Y Monthly)0.49
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Aimmune to Present at the Cantor Global Healthcare Conference

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m.

  • Business Wire

    FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use of AR101 (proposed trade name PALFORZIA™) in children and teens with peanut allergy. PALFORZIA is a complex, biologic oral immunotherapy (OIT) candidate designed to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy.

  • Business Wire

    Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration (FDA) Allergenic Products Advisory Committee (APAC) is holding a meeting today from 8:30 a.m. to 4:30 p.m. ET to discuss whether efficacy and safety data support licensure of PALFORZIA™ as a treatment to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients 4 through 17 years of age with a confirmed diagnosis of peanut allergy. The briefing materials can be found here on the FDA website.

  • Business Wire

    Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for AR101, an investigational biologic oral immunotherapy to reduce the frequency and severity of allergic reactions following exposure to peanuts in children and adolescents ages ...

  • Business Wire

    Aimmune to Present at the JMP Securities Life Sciences Conference

    Aimmune Therapeutics, Inc.  , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 2:30 p.m.

  • Business Wire

    Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at the Institute for Clinical and Economic Review’s (ICER) Public Meeting reviewing the effectiveness and value of treatments for peanut allergy, to be held today in Oakland, California. Aimmune is developing AR101, an investigational biologic drug for use in oral immunotherapy as a treatment to reduce the frequency and severity of allergic reactions following exposure to peanuts. Using only clinical data from the landmark Phase 3 PALISADE trial, ICER found AR101 to be cost-effective well-below ICER’s traditional threshold of $100,000-$150,000 per QALY.

  • Business Wire

    Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference

    Aimmune Therapeutics, Inc.  , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40th Annual Healthcare Conference on Wednesday, June 12, 2019 at 9:20 a.m.

  • Business Wire

    Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced new data from two studies that assessed the psychosocial burden of living with peanut allergy. Results from APPEAL 2, the first European multi-country qualitative evaluation of the impact of living with peanut allergy, found that living in fear of a potentially fatal reaction to peanuts significantly impacts the quality of life of individuals with peanut allergy and their families. AR101 is an investigational biologic drug for use in oral immunotherapy as a treatment to reduce the frequency and severity of allergic reactions following exposure to peanuts.

  • Business Wire

    New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced results from ARC004, an open-label, rollover study of the landmark Phase 3 PALISADE trial, which showed that extending daily therapy with AR101 by an additional 28 weeks led to improved tolerability with lower numbers of adverse events compared to the PALISADE therapeutic dosing period, an increase in the amount of peanut that could be safely ingested, and continued immunomodulation to peanut protein in most patients. AR101 is an investigational biologic drug for use in oral immunotherapy as a treatment to reduce the frequency and severity of allergic reactions following exposure to peanuts.

  • Business Wire

    Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had met its primary endpoint, demonstrating the efficacy and safety of AR101 in peanut-allergic children and adolescents after six months of dose escalation and a three-month therapeutic dosing phase. The findings from the ARTEMIS trial reinforce the consistent clinical profile of AR101, demonstrating that patients tolerated 1,000 mg of peanut protein after only nine months of treatment, which was the primary endpoint of the study.

  • Business Wire

    Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress

    – Full Results from Phase 3 ARTEMIS Study Will Be Featured –

  • Business Wire

    New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced results of a new study of U.S. adolescents with peanut allergy that found more than half required a visit to the emergency room or urgent care and one-third required hospitalization as a result of peanut exposure in the past 12 months, despite the fact that 100% of those surveyed reported actively avoiding peanut products. “These results illustrate how peanut avoidance, in practical day-to-day terms, provides neither the protection nor the confidence that patients are able to appropriately manage their disease in the real world,” said William McCann, M.D., senior author and Director, Vice President and Chief Medical Officer of Allergy Partners, the large single-specialty allergy practice in the U.S., focusing on treating asthma and allergic disease with locations across 20 states.

  • Business Wire

    Aimmune to Present at RBC Capital Markets Global Healthcare Conference

    Aimmune Therapeutics, Inc.  , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 2019, at 2:35 p.m.

  • Business Wire

    Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that the Allergenic Products Advisory Committee (APAC) will review the Biologics License Application (BLA) for AR101 at its meeting scheduled for September 13, 2019. Aimmune is developing AR101, an investigational biologic drug for use in oral immunotherapy, as a treatment to reduce the frequency and severity of adverse events, including anaphylaxis, following exposure to peanuts. Peanut allergy is one of the most common food allergies, affecting more than 1.6 million children and teens in the United States.1 It can be a chronic and life-long condition, and reactions to peanut are severe and potentially life-threatening.2 The threat of a severe reaction dominates families’ daily lives and interferes with their quality of life.

  • Business Wire

    Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights

    BRISBANE, Calif.-- -- Potential FDA approval of AR101 for peanut allergy expected by late January 2020; Company on target to be launch-ready in Q4 2019 Submission of marketing application for AR101 in Europe on track for mid-2019, following positive topline results of ARTEMIS European Phase 3 trial Initiation of AR201 phase 2 trial in egg allergy expected in mid-2019 Strong balance sheet expected to ...

  • Business Wire

    Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday, May 8, 2019, at 4:30 p.m.

  • Business Wire

    Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference

    Aimmune Therapeutics, Inc.  , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., President and Chief Executive Officer, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019, at 8:00 a.m.

  • Business Wire

    European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success), met its primary efficacy endpoint. Specifically, the median tolerated dose of peanut protein for AR101-treated patients improved 100-fold, from 10 mg at baseline to 1,000 mg at exit. In addition, the safety profile and completion rate observed in ARTEMIS are consistent with the results seen in previous AR101 clinical trials.

  • Business Wire

    U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the Biologics License Application (BLA) for AR101 has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA’s acceptance of our BLA is a crucial step forward in delivering AR101 to children, teens and families living with the serious, daily risk of allergic reactions to accidental exposure to peanuts,” said Jayson Dallas, M.D., President and Chief Executive Officer of Aimmune.

  • GlobeNewswire

    Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape

    NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.